Back to news

OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate

Globe Newswire•17/11/2026•07:00 ET
0

Key Highlights

  • ➤OXB confirms Aura partnership supporting bel-sar through Phase 3 development
  • ➤OXB initiated technical transfer ahead of process performance qualification and commercial production
  • ➤Aura’s bel-sar programme advances preparations for potential future commercial supply
  • ➤OXB will manufacture from FDA-approved commercial-scale Durham facility
  • ➤Partnership expands OXB into virus-like drug conjugate manufacturing

Expert Statements

Dr. Sebastien Ribault, Chief Business Officer of OXB

“As Aura advances bel-sar through Phase 3 development, a well-characterised and robust manufacturing process is critical.”

Dr. Sebastien Ribault, Chief Business Officer of OXB

“OXB brings extensive experience supporting complex viral vector programmes through process characterisation, PPQ and towards commercialisation.”

Dr. Sebastien Ribault, Chief Business Officer of OXB

“Supporting this promising candidate from our site in Durham, North Carolina, gives Aura experienced late-stage process and manufacturing teams at a site built for commercial-scale production.”

Dr. Sebastien Ribault, Chief Business Officer of OXB

“This also represents an exciting opportunity for OXB to step into VDC manufacturing, an adjacent segment that sits close to our core viral vector expertise and this partnership demonstrates our ability to provide a world-class service offering in this area.”

* Partnership established earlier this year supports Aura’s Phase 3 virus-like drug conjugates (VDC) client programme and preparations for potential future commercial supply * Programme builds on OXB’s extensive track record in process characterisation, PPQ and commercial-scale manufacturing * Programme is supported from OXB’s FDA-approved commercial-scale facility in Durham, North Carolina Oxford, UK – 17 November 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today confirm its manufacturing and supply partnership with Aura Biosciences, Inc. (“Aura”) (NASDAQ: AURA), a biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers. OXB is supporting late-stage development and manufacturing activities for Aura’s lead virus-like drug conjugate candidate, belzupacap sarotalocan (bel-sar), as Aura advances the programme through Phase 3 development and prepares for potential future commercial supply. Aura recently announced the partnership and its manufacturing strategy in its Q3 corporate update.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in